Multiple Myeloma

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discussing ongoing trials for patients with multiple myeloma.

Dan T. Vogl, MD, highlights the potential with CAR T-cell therapy in the multiple myeloma paradigm.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses genetic abnormalities in multiple myeloma.

A supplemental biologics license application has been submitted to the FDA for daratumumab for use in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.

Jayesh Mehta, MD, professor of medicine (hematology and oncology), Feinberg School of Medicine, discusses stem cell transplant in multiple myeloma.

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.

Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD.

Adam Waxman, MD, discusses emerging regimens for patients with multiple myeloma.

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discusses ongoing clinical trials for patients with myeloma.

Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

The FDA has granted GSK2857916 a breakthrough therapy designation for patients with relapsed/refractory multiple myeloma.

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

Jayesh Mehta, MD, discusses combination therapies in multiple myeloma, as well as the continued importance of stem cell transplant.

Ashley Rosko, MD, assistant professor in the Division of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment for elderly patients with multiple myeloma.

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Higher-dose, once-weekly carfilzomib (Kyprolis) demonstrated superior efficacy for patients with relapsed/refractory multiple myeloma compared with a lower-dose, twice-weekly regimen.

Maintenance therapy with lenalidomide following autologous stem-cell transplantation conferred a survival benefit for patients with newly diagnosed multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses properly managing patients with multiple myeloma.

Induction therapy with bortezomib, cyclophosphamide, and dexamethasone induced strong response rates in treatment-naïve patients with multiple myeloma.

Ashley Rosko, MD, discusses available therapies, others under investigation, and supportive care methods being utilized for patients with multiple myeloma.